Sabine Mandl-Taschner

St. Anna Children's Cancer Research Institute
Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Erratum: Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.

Erratum: Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.

Journal: JCO precision oncology

Published: July 16, 2026

Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.

Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.

Journal: JCO precision oncology

Published: July 01, 2026

Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.

Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.

Journal: The Journal of clinical investigation

Published: February 12, 2026

New biological insights into osteosarcoma-lessons from single cell sequencing studies.

New biological insights into osteosarcoma-lessons from single cell sequencing studies.

Journal: Cancer metastasis reviews

Published: November 24, 2025

MONALISA: A Privacy-Preserving Infrastructure Supporting Liquid Biopsies to Monitor Relapsed Neuroblastoma.

MONALISA: A Privacy-Preserving Infrastructure Supporting Liquid Biopsies to Monitor Relapsed Neuroblastoma.

Journal: Studies in health technology and informatics

Published: May 17, 2025

Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma: A SIOPEN Biology Study.

Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma: A SIOPEN Biology Study.

Journal: The Journal of molecular diagnostics : JMD

Published: April 08, 2025

Sensitive detection of minimal residual disease and immunotherapy targets by multi-modal bone marrow analysis in high-risk neuroblastoma - a multi-center study.

Sensitive detection of minimal residual disease and immunotherapy targets by multi-modal bone marrow analysis in high-risk neuroblastoma - a multi-center study.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 29, 2025

Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers.

Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers.

Journal: Cancer discovery

Published: November 26, 2024

Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.

Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.

Journal: The Journal of clinical investigation

Published: November 25, 2024

Risk stratification in neuroblastoma patients through machine learning in the multicenter PRIMAGE cohort.

Risk stratification in neuroblastoma patients through machine learning in the multicenter PRIMAGE cohort.

Journal: Frontiers in oncology

Published: November 15, 2024

BRAFV600E induces key features of LCH in iPSCs with cell type-specific phenotypes and drug responses.

BRAFV600E induces key features of LCH in iPSCs with cell type-specific phenotypes and drug responses.

Journal: Blood

Published: July 05, 2024

Reproducibility Analysis of Radiomic Features on T2-weighted MR Images after Processing and Segmentation Alterations in Neuroblastoma Tumors.

Reproducibility Analysis of Radiomic Features on T2-weighted MR Images after Processing and Segmentation Alterations in Neuroblastoma Tumors.

Journal: Radiology. Artificial intelligence

Published: June 12, 2024

Showing 1-12 of 48

Last Updated: 09/26/2026